Saturday 17 October 2026
Export MBRX’s income statement to Excel — free account
Moleculin Biotech, Inc.
MBRX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 95.1% and free cash flow fell 19.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.28
0.09
−24.32%
Follow MBRX
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
3.88 | 3.75 | 2.06 | 3.78 | 5.89 | 20.02 | 9.46 | 3.86 | 0.97 | 1.41 |
Net Debt/EBITDA |
1.22 | 0.89 | 0.48 | 0.62 | 0.78 | 3.11 | 1.41 | 0.80 | 0.16 | 0.35 |
Debt/Assets |
1.81% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.96 | 0.75 | 1.03 | 1.30 | 1.02 | 1.19 | 0.95 | 0.79 | 0.92 | 0.68 |
Capex/Depreciation |
(3.50) | (1.56) | (6.13) | (0.26) | (1.87) | (0.12) | (0.52) | (0.98) | (0.10) | 0.00 |
Interest Coverage |
(90.30) | — | (3,756.25) | (1,348.00) | (1,518.62) | (75.06) | (127.67) | — | — | — |
| (55.24%) | (61.13%) | (75.67%) | (88.50%) | (104.14%) | (32.85%) | (44.25%) | (76.07%) | (139.74%) | (256.84%) | |
| (47.82%) | (54.66%) | (60.80%) | (58.92%) | (63.96%) | (28.10%) | (41.02%) | (62.25%) | (94.48%) | (172.41%) | |
ROIC |
(23.68%) | (57.51%) | (131.56%) | (226.48%) | (476.95%) | (177.44%) | (211.70%) | (734.02%) | (240.27%) | (256.03%) |
Return on Tangible Assets |
(100.67%) | (160.21%) | (260.50%) | (129.08%) | (117.57%) | (22.96%) | (70.70%) | (150.88%) | 434,133.33% | (1,156.84%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.68 | 0.57 | 0.57 | 0.44 | 0.38 | 0.13 | 0.19 | 0.29 | 0.66 | 0.50 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(860.45) | (885.78) | (1,097.39) | (952.98) | (689.92) | (264.57) | (5,432.55) | (300.19) | (173.38) | (19.19) |
Cash per Share |
1,137.95 | 929.40 | 620.35 | 593.09 | 576.92 | 988.88 | 8,459.80 | 298.10 | 31.07 | 7.49 |
Shareholders Equity per Share |
3,400.00 | 2,062.41 | 1,241.04 | 860.28 | 675.29 | 1,101.72 | 10,233.53 | 330.04 | 81.39 | 12.67 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3,400.00 | 2,062.41 | 1,241.04 | 860.28 | 675.29 | 1,101.72 | 10,233.53 | 330.04 | 81.39 | 12.67 |
Free Cash Flow |
(3.79) | (7.35) | (12.62) | (17.25) | (18.14) | (18.97) | (27.71) | (23.71) | (23.87) | (22.73) |
Working Capital |
3.88 | 6.09 | 4.10 | 9.91 | 14.28 | 68.88 | 40.78 | 19.46 | (0.16) | 2.83 |
Capital Expenditures |
(0.02) | (0.03) | (0.42) | (0.05) | (0.37) | (0.02) | (0.07) | (0.12) | (0.01) | — |
Net Current Asset Value |
3.79 | 5.94 | 2.66 | 3.82 | 5.93 | 67.40 | 40.37 | 14.13 | (0.52) | 2.57 |
| Other line items | ||||||||||
Quick Ratio |
3.72 | 3.48 | 1.84 | 3.01 | 5.20 | 19.58 | 8.95 | 3.46 | 0.80 | 1.30 |
Depreciation/Fixed assets |
0.26 | 0.55 | 0.15 | 0.63 | 0.41 | 0.49 | 0.47 | 0.47 | 0.79 | 1.15 |
Cash ROIC |
(18.68%) | (29.61%) | (58.96%) | (65.57%) | (55.10%) | (12.66%) | (29.06%) | (47.79%) | (154.17%) | (95.19%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(855.68) | (882.41) | (1,061.13) | (950.17) | (675.70) | (264.31) | (5,419.41) | (298.62) | (173.29) | (19.19) |
Capex per Share |
(4.77) | (3.37) | (36.26) | (2.82) | (14.22) | (0.26) | (13.14) | (1.57) | (0.09) | 0.00 |
Average Receivables |
— | — | — | 0.01 | 0.01 | 0.02 | 0.03 | — | — | — |
Average Payables |
0.69 | 1.38 | 2.71 | 3.63 | 3.25 | 3.27 | 4.22 | 5.82 | 6.09 | 6.11 |
Average Assets |
8.21 | 17.94 | 19.53 | 22.41 | 27.13 | 56.56 | 70.76 | 47.82 | 27.57 | 19.53 |
Average Common Equity |
7.11 | 16.04 | 15.70 | 14.92 | 16.67 | 48.38 | 65.59 | 39.13 | 18.64 | 13.11 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates